Synologic, Inc announced that following disappointing top-line data from a phase 1b/2a study, the Company will discontinue the development of SYNB1020 for the treatment of hyperammonemia.
The randomized, double-blinded, placebo-controlled phase 1b/2a study consisted of two parts designed to evaluate the safety, tolerability, and pharmacodynamics of SYNB1020 in hepatic insufficiency and cirrhosis patients.
Results showed that although the investigational treatment was well-tolerated, SYNB1020 did not lower blood ammonia levels or change other exploratory end points associated with early stage hepatic encephalopathy in cirrhosis patients, compared with placebo. Detailed study results will be presented at a future medical conference.
“We are disappointed that results from our Phase 1b/2a study of SYNB1020 did not demonstrate an activity profile in ammonia lowering that warranted continued development of the program,” said Aoife Brennan, MB, BCh, Synlogic’s president and chief executive officer. “Moving forward, we will focus our resources on advancement of SYNB1618 for the treatment of phenylketonuria, SYNB1891 for the treatment of solid tumors and several new programs in early development.”
For more information visit synlogictx.com.
This article originally appeared on MPR